
A close-up of hands holding a tablet and a pen

Description automatically generated**U.S. Vagus nerve stimulation market**

According to Intelli, the U.S. Vagus nerve stimulation market size was valued at USD 273.95 Million in 2024 and is projected to reach USD 555.33 million by 2032, growing at a CAGR of 9.76% from 2025 to 2032.



In the intricate network of the human nervous system, the vagus nerve, the longest nerve, stands as a critical communication superhighway, linking the brain to vital organs like the heart, lungs, and digestive tract. Because of its far-reaching influence, the vagus nerve plays a central role in maintaining balance between mind and body. Functionally, the vagus nerve plays a central role in the parasympathetic nervous system, commonly known as the “rest and digest” system. It is instrumental in slowing the heart rate, facilitating digestion, regulating immune function, and promoting relaxation and recovery after stress. Vagus Nerve Stimulation (VNS) is a groundbreaking therapeutic approach that taps into this powerful neural pathway to modulate brain activity and restore balance in the body. Originally developed to treat drug-resistant epilepsy, VNS has since been approved for major depressive disorder and is being explored for a range of conditions including anxiety, migraines, inflammatory diseases, and heart failure. A typical VNS system consists of three main components including Pulse Generator, Lead Wire, and Programming System. It can be administered through surgically implanted devices or non-invasive external stimulators placed on the neck or ear. After implantation, the device emits controlled electrical pulses to the vagus nerve, which then transmits these signals to key areas of the brain involved in regulating mood, controlling seizures, and managing autonomic functions such as heart rate and digestion. By targeting the body’s communication superhighway, VNS offers a novel and often life-changing treatment path for patients who have exhausted conventional options.

**U.S. Vagus nerve stimulation market Definition**

​The U.S. Vagus Nerve Stimulation market refers to the segment of the medical device industry that focuses on the development, production, and commercialization of devices designed to deliver electrical impulses to the vagus nerve. The market includes both implantable VNS devices, which require surgical placement beneath the skin, and non-invasive external devices that deliver stimulation through the skin without the need for surgery.

A close-up of hands holding a tablet and a pen

Description automatically generated**U.S. Vagus nerve stimulation market Overview**

The U.S. Vagus Nerve Stimulation market has experienced notable growth in recent years. This growth is driven by factors such as technological advancements, increasing prevalence of neurological disorders, and expanding applications of VNS therapy. The rising incidence of conditions like epilepsy and depression has intensified the need for effective treatment options, leading to increased interest in therapies such as VNS. Advancements in device design and functionality have significantly enhanced patient outcomes and broadened the scope of VNS therapy. For example, the development of non-invasive VNS devices, such as gammaCore, has made it possible to treat conditions like cluster headaches and migraines without the need for surgical implantation, offering patients a safer, more accessible alternative. This financial support significantly reduces the out-of-pocket burden on patients, making the therapy more accessible to a larger population who might not have been able to afford it otherwise. By easing the economic barriers, expanded insurance coverage plays a key role in increasing adoption of VNS and improving overall health outcomes.

**U.S. Vagus nerve stimulation market Segmentation**

U.S. Vagus nerve stimulation market is segmented based on product type, application, and End-Users.

**U.S. Vagus nerve stimulation market, By Product Type**

* **Implantable VNS Devices**
* **External (Non-Invasive) VNS Devices**

The U.S. Vagus Nerve Stimulation market, when segmented by product type, is primarily divided into Implantable VNS Devices and External (Non-Invasive) VNS Devices**.** Implantable devices, which are surgically inserted under the skin and connected to the vagus nerve. In 2023, implantable VNS devices accounted for approximately 59.18% of the market share, reflecting their established role in treating conditions like epilepsy and depression. External (Non-Invasive) VNS Devices are revolutionizing the Vagus Nerve Stimulation (VNS) market by providing a non-surgical alternative to traditional implantable devices. These devices function by transmitting electrical pulses to the vagus nerve through the skin, often applied to areas such as the neck or ear. The increasing popularity of non-invasive VNS is fueled by their effectiveness in treating conditions like migraines, A close-up of hands holding a tablet and a pen

Description automatically generatedcluster headaches, and depression, all without the need for invasive surgery. This makes them an appealing choice for patients who seek safer, more convenient treatment options with fewer risks and simpler application.

**U.S. Vagus nerve stimulation market, By Application**

* **Epilepsy**
* **Depression**
* **Migraine & Cluster Headaches**
* **Inflammatory Conditions**

VNS therapy has been widely adopted for treating refractory epilepsy, particularly in patients unresponsive to conventional medications. The epilepsy segment dominated the market in 2022, highlighting its significant role in seizure management. For treatment-resistant depression, VNS provides a viable alternative when conventional antidepressants are ineffective. The depression segment also represents a significant portion of the market, highlighting the therapy's growing influence in addressing mood disorders. Non-invasive VNS devices have emerged as effective treatments for chronic migraines and cluster headaches, expanding the therapy's application beyond epilepsy and depression. This segment is experiencing notable growth, driven by the demand for non-surgical treatment options. The increasing adoption of VNS across these applications underscores its versatility and effectiveness in treating various neurological and psychiatric conditions, contributing to the robust growth of the U.S. VNS market.

**U.S. Vagus nerve stimulation market, By End-User**

* **Hospitals & Surgical Centers**
* **Specialty Clinics**
* **Homecare Settings**

The U.S. Vagus Nerve Stimulation (VNS) market, segmented by end-user, is primarily divided into Hospitals & Surgical Centers, Specialty Clinics, and Homecare Settings. Hospitals & Surgical Centers continue to dominate the market, as they are the primary settings for implanting VNS devices and managing post-operative care. These facilities offer specialized equipment and expertise for surgical procedures, making them essential for the successful implementation of implantable VNS devices. Specialty clinics A close-up of hands holding a tablet and a pen

Description automatically generatedspecializing in neurology, psychiatry, and pain management are becoming increasingly important, as they provide both implantable and non-invasive VNS treatments. Their focus on specialized therapies allows them to be at the forefront of adopting and advancing new treatment options, particularly in the evolving field of VNS. Homecare Settings are gaining traction, especially with the rise of non-invasive VNS devices, which allow patients to self-administer treatment in the comfort of their own homes. This segmentation reflects the market’s evolving landscape, with each setting playing a critical role in expanding access to VNS therapy.

**Key Players**

The “U.S. Vagus nerve stimulation market " study report will provide valuable insight emphasizing the U.S. market. The major players in the market LivaNova LLC, electroCore, Cerebral Rx, MicroTransponder, Inc., Parasym, BioControl, Innovative Health Solutions Inc., tVNS Technologies GmbH, Parasym, Soterix Medical Inc, Medtronic, Inc., Boston Scientific Corporation, NeuroPace, Inc., MicroTransponder Inc., Apollo Neuro, Cerbomed GmbH among others. Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.

**Key Developments**

* In 2024, SetPoint Medical earned FDA Breakthrough Device Designation for its implantable vagus nerve stimulation system, developed to treat relapsing-remitting multiple sclerosis. The system delivers targeted stimulation to the vagus nerve, triggering anti-inflammatory and immune-modulating responses to support disease management.
* In 2024, The FDA-approved Vivistim Paired VNS System from MicroTransponder has emerged as a game-changing treatment for stroke recovery. Implanted in the upper chest, the device coordinates vagus nerve stimulation with rehabilitation exercises to enhance motor function and accelerate recovery.

**Market Attractiveness**

The image of market attractiveness provided further helps to get information about the region leading in the U.S. Vagus nerve stimulation market. We cover the major impacting factors driving the industry growth in the given region.

**Porter’s Five Forces**

A close-up of hands holding a tablet and a pen

Description automatically generatedThe image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. Porter's five forces model can be used to assess the competitive landscape in the U.S. Vagus nerve stimulation market, gauge the attractiveness of a particular sector, and assess investment possibilities.

A close-up of hands holding a tablet and a pen

Description automatically generatedTABLE OF CONTENT

1 **INTRODUCTION OF U.S. VAGUS NERVE STIMULATION MARKET**

* 1. Overview of the market
  2. Scope of report
  3. Assumptions

1. **EXECUTIVE SUMMARY**
2. **RESEARCH METHODOLOGY**
   1. Data Mining
   2. Validation
   3. Primary Interviews
   4. List of Data sources
3. **U.S. VAGUS NERVE STIMULATION MARKET OUTLOOK**
   1. Overview
   2. Market Dynamics
      1. Drivers
      2. Restrains
      3. Opportunities
      4. Trends
   3. Portes Five FORCE Model
   4. Value Chain Analysis

**5 U.S. VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE**

5.1 Overview

5.2 Implantable VNS Devices

A close-up of hands holding a tablet and a pen

Description automatically generated5.3 External (Non-Invasive) VNS Devices

**6 U.S. VAGUS NERVE STIMULATION MARKET, BY APPLICATION**

6.1 Overview

6.2 Epilepsy

6.3 Depression

6.4 Migraine & Cluster Headaches

6.5 Inflammatory Conditions

**7 U.S. VAGUS NERVE STIMULATION MARKET, BY END-USER**

7.1 Overview

7.2 Hospitals and Clinics

7.3 Specialty Centers

7.4 Homecare Settings

1. **U.S. VAGUS NERVE STIMULATION MARKET COMPETITIVE LANDSCAPE**
   1. Overview
   2. Company Market Ranking
   3. Key Developments Strategies
2. **COMPANY PROFILES**

**9.1 LivaNova LLC**

* + 1. Overview
    2. Financial Performance
    3. A close-up of hands holding a tablet and a pen

       Description automatically generatedProduct Outlook
    4. Key developments
  1. **ElectroCore**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  2. **Cerebral Rx**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  3. **MicroTransponder, Inc**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  4. **Parasym**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  5. **BioControl**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. A close-up of hands holding a tablet and a pen

        Description automatically generatedKey developments
  6. **Innovative Health Solutions Inc**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  7. **tVNS Technologies GmbH**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments

* 1. **Parasym**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  2. **Soterix Medical Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  3. **Medtronic, Inc**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  4. **Boston Scientific Corporation**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  5. **NeuroPace, Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  6. **MicroTransponder Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  7. **Apollo Neuro**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  8. **Cerbomed GmbH**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments

1. **KEY DEVELOPMENTS**
   1. Product Launches/Developments
   2. Mergers and Acquisitions
   3. Business Expansions
   4. Partnerships and Collaborations
2. **Appendix**

11.1 Related Research